G308 Phase III Year 2 Patient Screening Starts

AI SummaryClose X

Allergy Therapeutics has commenced screening for the second year of its Phase III G308 trial, evaluating the long-term efficacy and safety of Grass MATA MPL in paediatric patients. The company aims to complete the screening and randomization period by early Q1 2026. The second year of recruitment aims for a similar number of participants as the first year, in which 190 participants were randomized. Short-term safety data from the first year is expected to be announced in Q4 2025, with a full analysis of short-term safety and efficacy results expected in Q4 2026. The company has invested over $100M in clinical development in grass allergy to date.

Disclaimer*

UK 100

Latest directors dealings